ATNX - アテネックス (Athenex Inc.) アテネックス

 ATNXのチャート


 ATNXの企業情報

symbol ATNx
会社名 Athenex Inc (アテネックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アテネックス(Athenex Inc.)は癌疾患および支持的療法向け治療法の開発および商品化に焦点を当てた腫瘍製薬会社である。同社の技術プラットフォームは経口吸収プラットフォーム、Srcキナーゼ阻害剤および症状治療薬の3つのカテゴリーに分類される。同社はパクリタキセルの経口製剤であるOraxol、イリノテカンの経口製剤であるOrateacan; オラドキセル、ドセタキセルの経口製剤、および各種タイプの癌治療用トポテカンの経口製剤を提供する。Srcキナーゼ阻害剤には、KX-01(KX2-391)およびKX-02(KX2-361)腫瘍薬候補が含まれる。同社の症状治療薬には、火傷や掻痒の治療用CQ-01、 照射誘発性皮膚炎の治療用CQ-R1、および化学療法誘発吐き気・嘔吐の治療用鼻腔内グラニセトロンを含む。   アテネックスは米国のバイオ医薬品企業。主にがん治療法の開発・商業化に従事する。同社製品の「Oraxol」は進行性胃がん治療用経口薬、「Oratecan」は大腸がん、肺がん、卵巣がん、子宮頸がん、膵臓がん治療の抗がん剤、「Oradoxel」は乳がん、前立腺がん、頭頸部がん、肺がん治療の抗がん剤などを含む。本社はニューヨーク州バッファロ―。   Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
本社所在地 1001 Main Street Suite 600 Buffalo NY 14203 USA
代表者氏名
代表者役職名
電話番号 +1 716-898-8625
設立年月日 41244
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 477人
url www.athenex.com
nasdaq_url https://www.nasdaq.com/symbol/atnx
adr_tso
EBITDA EBITDA(百万ドル) -84.80600
終値(lastsale) 14.43
時価総額(marketcap) 957329028.24
時価総額 時価総額(百万ドル) 945.38730
売上高 売上高(百万ドル) 78.26800
企業価値(EV) 企業価値(EV)(百万ドル) 866.22530
当期純利益 当期純利益(百万ドル) -61.51400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Athenex Inc revenues increased from $9.2M to $49.4M. Net loss decreased 45% to $44.2M. Revenues reflect Oncology Innovation Platform segment increase from $1M to $25.4M Commercial Platform segment increase from $1.9M to $15.7M United States segment increase from $2.9M to $17.8M Austria segment increase of 67% to $2.9M.

 ATNXのテクニカル分析


 ATNXのニュース

   All You Need to Know About Athenex (ATNX) Rating Upgrade to Strong Buy  2020/05/12 16:00:06 Zacks Investment Research
Athenex (ATNX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Athenex (ATNX): Strong Industry, Solid Earnings Estimate Revisions  2020/05/12 15:29:00 Zacks Investment Research
Athenex (ATNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Athenex (ATNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2020/04/30 16:34:45 Zacks Investment Research
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Athenex, Inc. (ATNX) Shares March Higher, Can It Continue?  2020/04/30 16:12:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Athenex, Inc. (ATNX).
   Athenex : Proxy Card | MarketScreener  2020/04/16 14:26:16 MarketScreener
ANNUAL MEETING OF ATHENEX, INC. Date:JUNE 5, 2020 Time:9:30 AM EDT … | April 16, 2020
   All You Need to Know About Athenex (ATNX) Rating Upgrade to Strong Buy  2020/05/12 16:00:06 Zacks Investment Research
Athenex (ATNX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Athenex (ATNX): Strong Industry, Solid Earnings Estimate Revisions  2020/05/12 15:29:00 Zacks Investment Research
Athenex (ATNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Athenex (ATNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2020/04/30 16:34:45 Zacks Investment Research
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Athenex, Inc. (ATNX) Shares March Higher, Can It Continue?  2020/04/30 16:12:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Athenex, Inc. (ATNX).
   Athenex : Proxy Card | MarketScreener  2020/04/16 14:26:16 MarketScreener
ANNUAL MEETING OF ATHENEX, INC. Date:JUNE 5, 2020 Time:9:30 AM EDT … | April 16, 2020
   All You Need to Know About Athenex (ATNX) Rating Upgrade to Strong Buy  2020/05/12 16:00:06 Zacks Investment Research
Athenex (ATNX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Athenex (ATNX): Strong Industry, Solid Earnings Estimate Revisions  2020/05/12 15:29:00 Zacks Investment Research
Athenex (ATNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Athenex (ATNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2020/04/30 16:34:45 Zacks Investment Research
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Athenex, Inc. (ATNX) Shares March Higher, Can It Continue?  2020/04/30 16:12:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Athenex, Inc. (ATNX).
   Athenex : Proxy Card | MarketScreener  2020/04/16 14:26:16 MarketScreener
ANNUAL MEETING OF ATHENEX, INC. Date:JUNE 5, 2020 Time:9:30 AM EDT … | April 16, 2020

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アテネックス ATNX Athenex Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)